A photo of Nikolai Timchenko.

Head of Liver Tumor Biology, Liver Tumor Program

Professor, UC Department of Surgery

513-636-0129

Biography & Affiliation

Biography

Nikolai A. Timchenko, PhD, came to Cincinnati Children’s Hospital Medical Center in June of 2014 from Baylor College of Medicine (BCM), where he was a professor of pathology and was working in the Huffington Center on aging.

Dr. Timchenko obtained his PhD in the Institute of Experimental Medicine in St. Petersburg, Russia in the field of liver biology and molecular genetics. After moving to the US, Dr. Timchenko worked at BCM as an assistant professor, associate professor, and full professor until 2014.

He is currently a professor in the Division of General and Thoracic Surgery at Cincinnati Children's within the UC Department of Surgery. Dr. Timchenko is also the director of the Liver Tumor Program. He investigates mechanisms of liver cancer in children and adults, mechanisms of NAFLD, and mechanisms of age-associated diseases.

Dr. Timchenko is a member of the Digestive Health Center (Cincinnati Children's) and a professor in the Department of Surgery at the University of Cincinnati.

Academic Affiliation

Professor, UC Department of Surgery

Research Divisions

General and Thoracic Surgery, Fibrosis

Education

PhD: Institute of Experimental Medicine, St. Petersburg, Russia.

Training: Post-Doc Fellow, Department of Pathology, Baylor College of Medicine, Houston, TX.

Publications

HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer. Rivas, M; Johnston, ME; Gulati, R; Kumbaji, M; Margues Aguiar, TF; Timchenko, L; Krepischi, A; Shin, S; Bondoc, A; Tiao, G; et al. CMGH Cellular and Molecular Gastroenterology and Hepatology. 2021; 12:1669-1682.

Help for Sick Kids: New Insights Into Hepatoblastoma. Timchenko, NA. CMGH Cellular and Molecular Gastroenterology and Hepatology. 2021; 12:350-351.

Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin. D’Souza, AM; Cast, A; Kumbaji, M; Rivas, M; Gulati, R; Johnston, M; Smithrud, D; Geller, J; Timchenko, N. Frontiers in Pharmacology. 2021; 12.

Molecular signatures of aggressive pediatric liver cancer. Johnston, ME; Timchenko, N. 2021; 2:1-4.

Hepatoblastomas exhibit marked NNMT downregulation driven by promoter DNA hypermethylation. Rivas, MP; Aguiar, TF M; Maschietto, M; Lemes, RB; Caires-Júnior, LC; Goulart, E; Telles-Silva, KA; Novak, E; Cristofani, LM; Odone, V; et al. Tumor Biology. 2020; 42.

Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice. Wang, M; Weng, W; Stock, L; Lindquist, D; Martinez, A; Gourdon, G; Timchenko, N; Snape, M; Timchenko, L. Molecular and Cellular Biology. 2019; 39.

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease. Cast, A; Kumbaji, M; D'Souza, A; Rodriguez, K; Gupta, A; Karns, R; Timchenko, L; Timchenko, N. Hepatology Communications. 2019; 3:1036-1049.

NR2E3 is a key component in p53 activation by regulating a long noncoding RNA DINO in acute liver injuries. Khanal, T; Leung, Y; Jiang, W; Timchenko, N; Ho, S; Kim, K. FASEB Journal. 2019; 33:8335-8348.

PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma. Valanejad, L; Cast, A; Wright, M; Bissig, K; Karns, R; Weirauch, MT; Timchenko, N. Communications Biology. 2018; 1.

Correction of aging phenotype in the liver. Rodriguez, K; Cast, A; Timchenko, NA. Aging. 2018; 10:1795-1796.